Research Papers:

Secondary malignancies after partial versus whole breast irradiation: a systematic review and meta-analysis

Xin-Bin Pan, Shi-Ting Huang, Yan-Ming Jiang, Jia-Lin Ma and Xiao-Dong Zhu _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:71951-71959. https://doi.org/10.18632/oncotarget.12442

Metrics: PDF 2280 views  |   HTML 1631 views  |   ?  


Xin-Bin Pan1, Shi-Ting Huang1, Yan-Ming Jiang1, Jia-Lin Ma1, Xiao-Dong Zhu1

1Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China

Correspondence to:

Xiao-Dong Zhu, email: [email protected]

Keywords: breast cancer, breast-conserving therapy, partial breast irradiation, whole breast irradiation, secondary malignancies

Received: August 26, 2016     Accepted: September 26, 2016     Published: October 04, 2016


Secondary malignancies are a common complication for patients receiving radiotherapy. Here, we compared rates of secondary malignancies after partial breast irradiation (PBI) and whole breast irradiation (WBI). The MEDLINE, EMBASE, and the Cochrane Library databases were systematically searched to identify relevant randomized clinical trials comparing PBI with WBI in breast cancer patients treated with breast-conserving therapy. Four studies including 2,185 patients were selected. Compared to WBI, the pooled odds ratios (OR) for contralateral breast cancer were 0.86 (95% confidence interval (CI) 0.31–2.42; p = 0.78) after 5 years and 1.15 (95% CI 0.43-3.09; p = 0.78) after 10 years for PBI. The pooled ORs for secondary non-breast cancer were 0.91 (95% CI 0.49-1.67; p = 0.77) after 5 years and 1.20 (95% CI 0.39-3.66; p = 0.75) after 10 years for PBI compared to WBI. These results demonstrate that the risk of secondary malignancies is similar for PBI and WBI after breast-conserving radiotherapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12442